TAKE growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
—−100.0%−65.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+74.4%+44.5%+29.2%
+74.4%+64.8%+40.5%
−71.0%+131.3%−19.2%
−71.1%+131.3%−19.2%
−0.7%−58.6%−60.7%
+51.0%+331.3%−108.2%
+74.8%−275.7%−53.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TAKE₹11.06

TAKE Limited

· Pharma & Health
₹ CrorePeersVIMTALABSSUVENMcap ₹164 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-65.3-100.0——
EBITDA Growth—+29.2+44.5+74.4—
EBIT Growth—+40.5+64.8+74.4—
Net Income Growth—-19.2+131.3-71.0—
EPS Growth—-19.2+131.3-71.1—
Total Assets Growth—-60.7-58.6-0.7—
Total Equity Growth—-108.2+331.3+51.0—
Cash from Operations Growth—-53.5-275.7+74.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.